Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Roche to sell flu pill for $50 to cash-paying US patients
    Finance

    Roche to Sell Flu Pill for $50 to Cash-Paying US Patients

    Published by Global Banking & Finance Review®

    Posted on October 16, 2025

    3 min read

    Last updated: January 21, 2026

    Add as preferred source on Google
    Roche to sell flu pill for $50 to cash-paying US patients - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:insurancehealthcareinnovation

    Quick Summary

    Roche offers Xofluza flu pill at $50 for cash-paying US patients, aiming to address drug pricing pressures.

    Roche Launches Xofluza Flu Pill for $50 to Cash-Paying Patients

    Roche's New Pricing Strategy for Xofluza

    By Patrick Wingrove

    Details of the Cash Price

    (Reuters) -Roche on Thursday launched direct-to-consumer U.S. sales of its influenza antiviral pill Xofluza at a discounted cash price of $50, following similar moves by rivals as they scramble to address pressure from the Trump administration to lower prescription drug prices paid by Americans.

    Impact on Patients and Market

    The Xofluza cash price, offered by Roche's U.S. biotech unit Genentech at 70% below list price, will be available to insured and uninsured patients through same-day delivery from Alto Pharmacy, Amazon Pharmacy, and Mark Cuban Cost Plus Drug Company. Major U.S. pharmacy chains like CVS will not be involved, Roche confirmed.

    Government Initiatives on Drug Pricing

    The administration of U.S. President Donald Trump has said it plans to launch, likely early next year, a website called TrumpRx that aims to help consumers buy some medicines directly from the manufacturers. Roche said its new program will not be accessible through TrumpRx, but that it will continue to evaluate its options.

    Few people in the U.S. pay cash for prescription medications. Most have insurance - either commercial or federal plans like Medicare - that charge them a fixed co-pay or percentage of a drug cost. Insurers typically receive confidential discounts or rebates directly from drug manufacturers, bringing their costs well below list prices.

    The Swiss drugmaker already offers a coupon for Xofluza that brings the out-of-pocket cost down to $35 for some insured and uninsured patients.

    Xofluza is used to treat flu in patients aged 12 years and older who have had symptoms for no more than two days.

    Trump, in an effort to lower drug costs for U.S. patients who pay far more than in other wealthy nations, has so far struck deals with Pfizer and AstraZeneca to lower their prescription drug prices in the Medicaid program for lower-income Americans in exchange for tariff relief.

    Roche said its new program supports that goal and is similar to one from rival Amgen, which launched discounts for cash-paying patients this year.

    Analysts expect Xofluza to generate $340 million in sales this year.

    Roche, via Genentech, was one of 17 major drug companies to receive a letter from Trump in July demanding they charge U.S. patients the same price as people pay in other high-income countries, create direct-to-consumer channels and increase investment in the U.S. Trump threatened to impose 100% tariffs on branded drugs to those companies that failed to comply.

    (Reporting by Patrick WingroveEditing by Bill Berkrot)

    Table of Contents

    • Roche's New Pricing Strategy for Xofluza
    • Details of the Cash Price
    • Impact on Patients and Market
    • Government Initiatives on Drug Pricing

    Key Takeaways

    • •Roche launches Xofluza at $50 for cash-paying US patients.
    • •The price is 70% below the list price.
    • •Available through Alto, Amazon, and Mark Cuban pharmacies.
    • •Not available through major chains like CVS.
    • •Part of Roche's response to US drug pricing pressures.

    Frequently Asked Questions about Roche to sell flu pill for $50 to cash-paying US patients

    1What is Xofluza?

    Xofluza is an antiviral medication used to treat influenza in patients aged 12 years and older who have had symptoms for no more than two days.

    2What is a cash price?

    A cash price refers to the amount a consumer pays for a product or service without using insurance or financing options, often resulting in lower costs.

    3What are prescription drug prices?

    Prescription drug prices are the costs associated with medications that require a doctor's prescription, which can vary based on insurance coverage and manufacturer pricing.

    4What is a coupon in pharmaceuticals?

    A coupon in pharmaceuticals is a discount offer provided by drug manufacturers to reduce the out-of-pocket cost for patients purchasing medications.

    5What is direct-to-consumer sales?

    Direct-to-consumer sales refer to the practice of selling products or services directly to consumers without intermediaries, often through online platforms or pharmacies.

    More from Finance

    Explore more articles in the Finance category

    Image for Germany's EnBW expects profits to be stable at best in 2026
    Germany's EnBW Expects Profits to Be Stable at Best in 2026
    Image for UK, EU and Switzerland set out one-day settlement testing plan
    Uk, EU and Switzerland Set Out One-Day Settlement Testing Plan
    Image for Taiwan wary that China could exploit US distraction over Middle East war
    Taiwan Wary That China Could Exploit US Distraction Over Middle East War
    Image for Russian attacks knock out power for thousands in Ukraine's north
    Russian Attacks Knock Out Power for Thousands in Ukraine's North
    Image for UK's Headlam warns of revenue drop as Middle East war pushes costs higher
    UK's Headlam Warns of Revenue Drop as Middle East War Pushes Costs Higher
    Image for Hedge fund founder Odey gives evidence in fight against financial industry ban
    Hedge Fund Founder Odey Gives Evidence in Fight Against Financial Industry Ban
    Image for UK's RS Group forecasts annual profit marginally ahead of market view
    UK's Rs Group Forecasts Annual Profit Marginally Ahead of Market View
    Image for Spanish gambling group Codere to go on sale for $2.3 billion, Expansion reports
    Spanish Gambling Group Codere to Go on Sale for $2.3 Billion, Expansion Reports
    Image for UK's ASOS posts 50% profit surge on cost-focussed revamp
    UK's Asos Posts 50% Profit Surge on Cost-Focussed Revamp
    Image for UK inflation holds at 3.0% in February
    UK Inflation Holds at 3.0% in February
    Image for Fastweb + Vodafone terminates agreement with INWIT
    Fastweb + Vodafone Terminates Agreement With Inwit
    Image for Asia looks to COVID-era playbook to tackle fuel crisis
    Asia Looks to COVID-era Playbook to Tackle Fuel Crisis
    View All Finance Posts
    Previous Finance PostAbb CEO 'very Confident' of Demand for Data Centers Powering AI
    Next Finance PostPortugal's Proposal for EDP's Grid Returns Still Lags European Peers